Scinai Immunotherapeutics Ltd.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Scinai Immunotherapeutics Ltd. now
Current reporting with the operating signal separated from the noise.
Scinai Immunotherapeutics Ltd. ADR
The development tests whether Scinai Immunotherapeutics Ltd. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Scinai Immunotherapeutics Ltd (SCNI) Earnings Forecast: Future EPS & Revenue Growth Estimates
Investors are testing whether Scinai Immunotherapeutics Ltd.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.SCNI|Scinai Immunotherapeutics Ltd|Price:0.263|Chg%:-0.013
The development tests whether Scinai Immunotherapeutics Ltd. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Scinai Immunotherapeutics Ltd (SCNI) Risk Assessment: Volatility, Financial Risk & Investment Risk
The development tests whether Scinai Immunotherapeutics Ltd. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Scinai Immunotherapeutics Ltd (SCNI) Financial Health: Profitability & Balance Sheet Analysis
Investors are testing whether Scinai Immunotherapeutics Ltd.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Scinai Immunotherapeutics Ltd.: Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
The development tests whether Scinai Immunotherapeutics Ltd. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript
Investors are testing whether Scinai Immunotherapeutics Ltd.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
The development tests whether Scinai Immunotherapeutics Ltd. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
The development tests whether Scinai Immunotherapeutics Ltd. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Latest SCNI filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Scinai Immunotherapeutics Ltd., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →